Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #51 to #550.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Absorbed fraction‏‎ (5 revisions)
  2. Effective half-life‏‎ (4 revisions)
  3. Averted dose‏‎ (4 revisions)
  4. Kp index‏‎ (4 revisions)
  5. Protective action‏‎ (4 revisions)
  6. Reference Animal and Plant‏‎ (4 revisions)
  7. Source-related assessment‏‎ (4 revisions)
  8. Forbiddenness‏‎ (4 revisions)
  9. Aerodynamic diameter‏‎ (4 revisions)
  10. ICRP‏‎ (4 revisions)
  11. Diagnostic reference level‏‎ (4 revisions)
  12. Risk‏‎ (4 revisions)
  13. Senescence‏‎ (4 revisions)
  14. Reference bioassay function‏‎ (4 revisions)
  15. Air-kerma, product‏‎ (4 revisions)
  16. Fractionation sensitivity‏‎ (4 revisions)
  17. Optimisation‏‎ (4 revisions)
  18. Sievert‏‎ (4 revisions)
  19. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  20. S coefficient (radiation weighted)‏‎ (4 revisions)
  21. Non-maleficence‏‎ (4 revisions)
  22. High linear energy transfer radiation‏‎ (4 revisions)
  23. Direct bioassay‏‎ (4 revisions - redirect page)
  24. Bioassay‏‎ (4 revisions)
  25. Calculating Radon Doses‏‎ (4 revisions)
  26. Computed tomography dose index‏‎ (4 revisions)
  27. Mass median diameter‏‎ (4 revisions)
  28. Alpha decay‏‎ (4 revisions)
  29. Effective charge number‏‎ (4 revisions)
  30. Math‏‎ (4 revisions)
  31. Programmed cell death‏‎ (4 revisions)
  32. Dose equivalent‏‎ (3 revisions)
  33. Field-size effect (Volume effect)‏‎ (3 revisions)
  34. Gastrointestinal syndrome‏‎ (3 revisions)
  35. Wisdom‏‎ (3 revisions)
  36. Biomedical research volunteer‏‎ (3 revisions)
  37. Cardiomyopathy‏‎ (3 revisions)
  38. Dose limit‏‎ (3 revisions)
  39. Target region‏‎ (3 revisions)
  40. Flexible tissues‏‎ (3 revisions)
  41. Guide to the System of Radiological Protection‏‎ (3 revisions)
  42. Autonomy‏‎ (3 revisions)
  43. Dose‏‎ (3 revisions)
  44. Dose limits‏‎ (3 revisions)
  45. Fluence‏‎ (3 revisions)
  46. Constancy test‏‎ (3 revisions)
  47. DS02‏‎ (3 revisions)
  48. Fluoroscopically guided interventions‏‎ (3 revisions)
  49. Annual dose‏‎ (3 revisions)
  50. Potential exposure‏‎ (3 revisions)
  51. Rigidity threshold‏‎ (3 revisions)
  52. Dose of record (E)‏‎ (3 revisions)
  53. Low Earth orbit‏‎ (3 revisions)
  54. Accountability‏‎ (3 revisions)
  55. X ray‏‎ (3 revisions)
  56. Half-life, physical‏‎ (3 revisions)
  57. Cell death‏‎ (3 revisions)
  58. Contamination‏‎ (3 revisions)
  59. Exponential survival curve‏‎ (3 revisions)
  60. Unsealed source‏‎ (3 revisions)
  61. Xerostomia‏‎ (3 revisions)
  62. Annual limit on intake‏‎ (3 revisions)
  63. Dose per content function‏‎ (3 revisions)
  64. Interphase death‏‎ (3 revisions)
  65. Equity‏‎ (3 revisions)
  66. Test‏‎ (3 revisions)
  67. Graded approach‏‎ (3 revisions)
  68. Public exposure‏‎ (3 revisions)
  69. Fractionation‏‎ (3 revisions)
  70. Uptake‏‎ (3 revisions)
  71. Active (red) bone marrow‏‎ (3 revisions)
  72. Utilitarian ethics‏‎ (3 revisions)
  73. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  74. Operational quantity‏‎ (3 revisions)
  75. Value judgement‏‎ (3 revisions)
  76. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  77. Coster-Kronig transition‏‎ (3 revisions)
  78. Emergency preparedness‏‎ (3 revisions)
  79. Valvular heart disease‏‎ (3 revisions)
  80. Gray‏‎ (3 revisions)
  81. Personal dose equivalent‏‎ (3 revisions)
  82. Principle of justification‏‎ (3 revisions)
  83. Radiofrequency ablation‏‎ (3 revisions)
  84. Iso-effect plots‏‎ (3 revisions)
  85. Emergency procedures‏‎ (3 revisions)
  86. Lifetime risk estimates‏‎ (3 revisions)
  87. Absolute risk‏‎ (3 revisions)
  88. Virtue ethics‏‎ (3 revisions)
  89. Auger transition‏‎ (3 revisions)
  90. Bystander effect‏‎ (3 revisions)
  91. Derived air concentration‏‎ (3 revisions)
  92. Dignity‏‎ (3 revisions)
  93. Isomers‏‎ (3 revisions)
  94. Employer‏‎ (3 revisions)
  95. Activity median thermodynamic diameter‏‎ (3 revisions)
  96. Voxel phantom‏‎ (3 revisions)
  97. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  98. Complex tissues‏‎ (3 revisions)
  99. Growth fraction‏‎ (3 revisions)
  100. Organ dose equivalent‏‎ (3 revisions)
  101. Excretion rate (instantaneous)‏‎ (3 revisions)
  102. Extrathoracic airways‏‎ (3 revisions)
  103. Galactic cosmic radiation‏‎ (3 revisions)
  104. Growth hormone (somatotropin)‏‎ (3 revisions)
  105. ICRP Publication 103‏‎ (3 revisions)
  106. Spread-out Bragg peak‏‎ (3 revisions)
  107. Fairness‏‎ (3 revisions)
  108. Absorption‏‎ (3 revisions)
  109. Gamma ray‏‎ (3 revisions)
  110. Recovery‏‎ (3 revisions)
  111. DNA damage signalling‏‎ (3 revisions)
  112. Retrievability‏‎ (2 revisions)
  113. Immune system‏‎ (2 revisions)
  114. Institutional control‏‎ (2 revisions)
  115. Stakeholder‏‎ (2 revisions)
  116. Environmental radiation protection‏‎ (2 revisions)
  117. Tachycardia‏‎ (2 revisions)
  118. Exemption level‏‎ (2 revisions)
  119. Tissue equivalent material‏‎ (2 revisions)
  120. Myocardial stress test‏‎ (2 revisions)
  121. Oversight‏‎ (2 revisions)
  122. Projected dose‏‎ (2 revisions)
  123. Co-expertise‏‎ (2 revisions)
  124. Radionuclides of natural origin‏‎ (2 revisions)
  125. Connective tissue‏‎ (2 revisions)
  126. Recovery (cellular or tissue)‏‎ (2 revisions)
  127. DRL process‏‎ (2 revisions)
  128. Reversibility‏‎ (2 revisions)
  129. In vivo radiobioassay‏‎ (2 revisions)
  130. Solar particle event‏‎ (2 revisions)
  131. Effective dose equivalent‏‎ (2 revisions)
  132. Existing exposure situation‏‎ (2 revisions)
  133. Gastroschisis‏‎ (2 revisions)
  134. Worker‏‎ (2 revisions)
  135. Nuclear track detectors‏‎ (2 revisions)
  136. Angiogenesis‏‎ (2 revisions)
  137. Hyperbaric oxygen‏‎ (2 revisions)
  138. Bioturbation‏‎ (2 revisions)
  139. Cardioverter-defibrillator‏‎ (2 revisions)
  140. Radiation safety officer‏‎ (2 revisions)
  141. Radioresponsiveness‏‎ (2 revisions)
  142. Consequential late effects‏‎ (2 revisions)
  143. Recovery responder‏‎ (2 revisions)
  144. Rehabilitation of living conditions‏‎ (2 revisions)
  145. Right to know‏‎ (2 revisions)
  146. Incidence‏‎ (2 revisions)
  147. Solar wind‏‎ (2 revisions)
  148. Epithelium‏‎ (2 revisions)
  149. Target tissue‏‎ (2 revisions)
  150. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  151. Acceptance test‏‎ (2 revisions)
  152. Gastrulation‏‎ (2 revisions)
  153. Working level‏‎ (2 revisions)
  154. OLINDA/EXM‏‎ (2 revisions)
  155. Habitual mouth breather‏‎ (2 revisions)
  156. Annihilation photons‏‎ (2 revisions)
  157. Particle radiance‏‎ (2 revisions)
  158. Hyperfractionation‏‎ (2 revisions)
  159. Bone marrow‏‎ (2 revisions)
  160. Protection strategy‏‎ (2 revisions)
  161. Radiation source‏‎ (2 revisions)
  162. Cohort study‏‎ (2 revisions)
  163. Radiosensitiser‏‎ (2 revisions)
  164. DRL value‏‎ (2 revisions)
  165. Rigidity‏‎ (2 revisions)
  166. Dose-length product‏‎ (2 revisions)
  167. Security‏‎ (2 revisions)
  168. Incident‏‎ (2 revisions)
  169. Intermediate level waste‏‎ (2 revisions)
  170. Stenosis‏‎ (2 revisions)
  171. Equieffective dose‏‎ (2 revisions)
  172. Local DRL‏‎ (2 revisions)
  173. Expanded and aligned radiation field‏‎ (2 revisions)
  174. Tolerability‏‎ (2 revisions)
  175. Medical exposure‏‎ (2 revisions)
  176. Naturally occurring radioactive material‏‎ (2 revisions)
  177. Adventitious‏‎ (2 revisions)
  178. Working level month‏‎ (2 revisions)
  179. Habitual nose breather‏‎ (2 revisions)
  180. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  181. Background dose (rate)‏‎ (2 revisions)
  182. Radiosensitivity, cellular‏‎ (2 revisions)
  183. Containment‏‎ (2 revisions)
  184. Detriment‏‎ (2 revisions)
  185. Dose-rate effect‏‎ (2 revisions)
  186. Inclusiveness‏‎ (2 revisions)
  187. Source-related‏‎ (2 revisions)
  188. Internal conversion electron‏‎ (2 revisions)
  189. Electron-capture decay‏‎ (2 revisions)
  190. LD 50/30‏‎ (2 revisions)
  191. Telangiectasia‏‎ (2 revisions)
  192. Member of the public‏‎ (2 revisions)
  193. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  194. Unattached fraction‏‎ (2 revisions)
  195. Necrosis‏‎ (2 revisions)
  196. Patient entrance reference point‏‎ (2 revisions)
  197. Hypoplasia‏‎ (2 revisions)
  198. Backscatter detection system‏‎ (2 revisions)
  199. Potential recoverability correction factor‏‎ (2 revisions)
  200. Bradycardia‏‎ (2 revisions)
  201. Protective action guide‏‎ (2 revisions)
  202. Radiation worker‏‎ (2 revisions)
  203. Decay constant‏‎ (2 revisions)
  204. Self-help protection‏‎ (2 revisions)
  205. Individual-related‏‎ (2 revisions)
  206. Dose of record Hp (10)‏‎ (2 revisions)
  207. Electrophysiology‏‎ (2 revisions)
  208. Storage‏‎ (2 revisions)
  209. Track structure‏‎ (2 revisions)
  210. Mendelian diseases‏‎ (2 revisions)
  211. Accreditation‏‎ (2 revisions)
  212. Neurological syndrome‏‎ (2 revisions)
  213. Genomic integrity‏‎ (2 revisions)
  214. Occupational exposure‏‎ (2 revisions)
  215. Hazard‏‎ (2 revisions)
  216. Peak skin dose‏‎ (2 revisions)
  217. Bragg peak‏‎ (2 revisions)
  218. Radioactive dispersion device‏‎ (2 revisions)
  219. Radon: Units of Measure‏‎ (2 revisions)
  220. Coronary heart disease‏‎ (2 revisions)
  221. Reference air kerma‏‎ (2 revisions)
  222. Decommissioning‏‎ (2 revisions)
  223. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  224. Dose-threshold‏‎ (2 revisions)
  225. Individual decontamination‏‎ (2 revisions)
  226. Subcutaneous tissue‏‎ (2 revisions)
  227. Low dose rate‏‎ (2 revisions)
  228. Transfer compartment‏‎ (2 revisions)
  229. Mitigation‏‎ (2 revisions)
  230. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  231. Action Level‏‎ (2 revisions)
  232. Upper reference levels‏‎ (2 revisions)
  233. Neurovascular syndrome‏‎ (2 revisions)
  234. Health Surveillance‏‎ (2 revisions)
  235. Pelagic‏‎ (2 revisions)
  236. Basal cell‏‎ (2 revisions)
  237. Practical radiological protection culture‏‎ (2 revisions)
  238. Branching fraction‏‎ (2 revisions)
  239. Chronic exposure‏‎ (2 revisions)
  240. Radioactive source‏‎ (2 revisions)
  241. Colony‏‎ (2 revisions)
  242. Cosmic Radiation in Aviation‏‎ (2 revisions)
  243. Decontamination‏‎ (2 revisions)
  244. Relocation‏‎ (2 revisions)
  245. Diastasis‏‎ (2 revisions)
  246. Risk coefficient‏‎ (2 revisions)
  247. Individual monitoring‏‎ (2 revisions)
  248. Dose per unit intake coefficient‏‎ (2 revisions)
  249. Source term‏‎ (2 revisions)
  250. Emergency‏‎ (2 revisions)
  251. Latent time/period or latency interval‏‎ (2 revisions)
  252. Low level waste‏‎ (2 revisions)
  253. Exposure, external or internal‏‎ (2 revisions)
  254. Graft vs host disease‏‎ (2 revisions)
  255. Air-kerma, incident‏‎ (2 revisions)
  256. Heliosphere‏‎ (2 revisions)
  257. Qualified expert‏‎ (2 revisions)
  258. Class SR-0 gases‏‎ (2 revisions)
  259. Radioactive substance‏‎ (2 revisions)
  260. Reference biokinetic model‏‎ (2 revisions)
  261. Decontamination factor‏‎ (2 revisions)
  262. Remedial action‏‎ (2 revisions)
  263. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  264. Dose rate‏‎ (2 revisions)
  265. Intervention Level‏‎ (2 revisions)
  266. Emergency exposure situation‏‎ (2 revisions)
  267. Substantial radiation dose level‏‎ (2 revisions)
  268. Erythropoietin‏‎ (2 revisions)
  269. Exposure (in the context of inhalation)‏‎ (2 revisions)
  270. Transfer rate‏‎ (2 revisions)
  271. Multi-detector computed tomography‏‎ (2 revisions)
  272. Fractionation and dose delivery patterns‏‎ (2 revisions)
  273. Percutaneous coronary intervention‏‎ (2 revisions)
  274. Prevailing circumstances‏‎ (2 revisions)
  275. Broad beam therapy irradiation technique‏‎ (2 revisions)
  276. Class SR-1 gases‏‎ (2 revisions)
  277. Committed effective dose‏‎ (2 revisions)
  278. Radon Recommendations for Authorities‏‎ (2 revisions)
  279. Cost-benefit analysis‏‎ (2 revisions)
  280. Reference individual‏‎ (2 revisions)
  281. Remediation‏‎ (2 revisions)
  282. Dichotomous‏‎ (2 revisions)
  283. Risk of Exposure to Radon‏‎ (2 revisions)
  284. Dose rate effectiveness factor‏‎ (2 revisions)
  285. South Atlantic anomaly‏‎ (2 revisions)
  286. Interventional procedure‏‎ (2 revisions)
  287. Emergency plan‏‎ (2 revisions)
  288. Ethics‏‎ (2 revisions)
  289. Lymphatic system‏‎ (2 revisions)
  290. ALARA‏‎ (2 revisions)
  291. Transforming growth factor‏‎ (2 revisions)
  292. Hierarchical tissues‏‎ (2 revisions)
  293. Area monitoring‏‎ (2 revisions)
  294. Pericarditis‏‎ (2 revisions)
  295. Benthic‏‎ (2 revisions)
  296. Principle of application of dose limits‏‎ (2 revisions)
  297. Bronchial region‏‎ (2 revisions)
  298. Class SR-2 gases‏‎ (2 revisions)
  299. Radioactivity‏‎ (2 revisions)
  300. Committed equivalent dose‏‎ (2 revisions)
  301. Radon Recommendations for Workplaces‏‎ (2 revisions)
  302. Reference level‏‎ (2 revisions)
  303. Deontological Ethics‏‎ (2 revisions)
  304. Repopulation‏‎ (2 revisions)
  305. Differentiation‏‎ (2 revisions)
  306. Routine monitoring‏‎ (2 revisions)
  307. ICRPædia Guide to Radon‏‎ (2 revisions)
  308. Special (non-routine) monitoring‏‎ (2 revisions)
  309. Lifetime risk‏‎ (2 revisions)
  310. Macrophage colony stimulating factor‏‎ (2 revisions)
  311. Multiplicative risk projection model‏‎ (2 revisions)
  312. Activity‏‎ (2 revisions)
  313. High level waste‏‎ (2 revisions)
  314. Clearance‏‎ (2 revisions)
  315. Representative organism (non-human biota)‏‎ (2 revisions)
  316. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  317. Dose constraint‏‎ (2 revisions)
  318. Early normal tissue responses‏‎ (2 revisions)
  319. Threshold dose for tissue reactions‏‎ (2 revisions)
  320. Magnetosphere‏‎ (2 revisions)
  321. Beta-minus decay‏‎ (2 revisions)
  322. Clearance level‏‎ (2 revisions)
  323. Radiographer‏‎ (2 revisions)
  324. Representative person‏‎ (2 revisions)
  325. Safety‏‎ (2 revisions)
  326. Dose conversion coefficient‏‎ (2 revisions)
  327. Edema‏‎ (2 revisions)
  328. Specific effective energy‏‎ (2 revisions)
  329. Limitation of dose‏‎ (2 revisions)
  330. Excess relative risk‏‎ (2 revisions)
  331. Exposure situation‏‎ (2 revisions)
  332. Transmission detection system‏‎ (2 revisions)
  333. Multistage tumorigenesis‏‎ (2 revisions)
  334. Non-sphericity parameter‏‎ (2 revisions)
  335. Growth factor‏‎ (2 revisions)
  336. Alimentary tract transfer factor‏‎ (2 revisions)
  337. Pharynx‏‎ (2 revisions)
  338. Beta-plus decay‏‎ (2 revisions)
  339. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  340. Cumulative dose‏‎ (2 revisions)
  341. Reproductive integrity‏‎ (2 revisions)
  342. Safety case‏‎ (2 revisions)
  343. Slow repair‏‎ (2 revisions)
  344. Effect Dose 50‏‎ (2 revisions)
  345. Isotropic geometry‏‎ (2 revisions)
  346. Endogeneous excretion‏‎ (2 revisions)
  347. Lineal energy‏‎ (2 revisions)
  348. Thyroid blocking‏‎ (2 revisions)
  349. Exposure to Radon at Home‏‎ (2 revisions)
  350. Transparency‏‎ (2 revisions)
  351. GATA binding protein 2‏‎ (2 revisions)
  352. Waste disposal‏‎ (2 revisions)
  353. Non-targeted effects‏‎ (2 revisions)
  354. Hormones‏‎ (2 revisions)
  355. Authorization‏‎ (2 revisions)
  356. Procedural values‏‎ (2 revisions)
  357. Clonogenic cells‏‎ (2 revisions)
  358. Curie‏‎ (2 revisions)
  359. Residual dose‏‎ (2 revisions)
  360. Safety culture‏‎ (2 revisions)
  361. Solar cosmic radiation‏‎ (2 revisions)
  362. Inhalability‏‎ (2 revisions)
  363. Spontaneous fission‏‎ (2 revisions)
  364. Itinerant (radiation) worker‏‎ (2 revisions)
  365. Linear-non-threshold model‏‎ (2 revisions)
  366. Trapped particles‏‎ (2 revisions)
  367. Acute radiation syndrome‏‎ (2 revisions)
  368. Orphan source‏‎ (2 revisions)
  369. Hounsfield unit‏‎ (2 revisions)
  370. Authorized limit‏‎ (2 revisions)
  371. Planned exposure situation‏‎ (2 revisions)
  372. Progenitor cell‏‎ (2 revisions)
  373. Cardiac arrhythmias‏‎ (2 revisions)
  374. Radiation belt‏‎ (2 revisions - redirect page)
  375. Clonogenic survival‏‎ (2 revisions)
  376. Reasonableness‏‎ (2 revisions)
  377. Cytokines‏‎ (2 revisions)
  378. Respiratory protection‏‎ (2 revisions)
  379. Disposal‏‎ (2 revisions)
  380. Scintigraphy‏‎ (2 revisions)
  381. Dose criteria‏‎ (2 revisions)
  382. Solar cycle‏‎ (2 revisions)
  383. Inner bremsstrahlung‏‎ (2 revisions)
  384. Environmental exposure‏‎ (2 revisions)
  385. Systemic model‏‎ (2 revisions)
  386. Linear-quadratic dose response model‏‎ (2 revisions)
  387. Exempt waste‏‎ (2 revisions)
  388. Time factor‏‎ (2 revisions)
  389. Myocardial perfusion‏‎ (2 revisions)
  390. Adaptive response‏‎ (2 revisions)
  391. What is Radon?‏‎ (2 revisions)
  392. Alveolar-interstitial region‏‎ (2 revisions)
  393. Autoimmune disease‏‎ (2 revisions)
  394. Platelet-derived growth factor‏‎ (2 revisions)
  395. ICRP Publication 118‏‎ (2 revisions)
  396. Cardiac valve diseases‏‎ (2 revisions)
  397. Radiation modifier‏‎ (2 revisions)
  398. Radiological protection principles‏‎ (2 revisions)
  399. Regional diagnostic reference levels‏‎ (1 revision)
  400. ICRP Publication 30 (Supplement B to Part 3)‏‎ (1 revision)
  401. Derived reference level‏‎ (1 revision)
  402. ICRP Publication 95‏‎ (1 revision)
  403. ICRP Publication 43‏‎ (1 revision)
  404. Disposal facility‏‎ (1 revision)
  405. Sealed source‏‎ (1 revision)
  406. ICRP Publication 58‏‎ (1 revision)
  407. Solar flare‏‎ (1 revision)
  408. ICRP Publication 72‏‎ (1 revision)
  409. ICRP Publication 87‏‎ (1 revision)
  410. Linear dose response‏‎ (1 revision)
  411. Mean glandular dose‏‎ (1 revision)
  412. Absorption Type‏‎ (1 revision - redirect page)
  413. Trophic level‏‎ (1 revision)
  414. Additional dose‏‎ (1 revision)
  415. Nuclear medicine‏‎ (1 revision)
  416. Ambient dose equivalent‏‎ (1 revision)
  417. Human Respiratory Tract Model‏‎ (1 revision)
  418. Automatic exposure control‏‎ (1 revision)
  419. Pooled analysis‏‎ (1 revision)
  420. ICRP Publication 105‏‎ (1 revision)
  421. ICRP Publication 119‏‎ (1 revision)
  422. Radiation risk‏‎ (1 revision)
  423. ICRP Publication 133‏‎ (1 revision)
  424. ICRP Publication 148‏‎ (1 revision)
  425. ICRP Publication 22‏‎ (1 revision)
  426. Registry‏‎ (1 revision)
  427. ICRP Publication 30 (Supplement to Part 1)‏‎ (1 revision)
  428. Designated area‏‎ (1 revision)
  429. ICRP Publication 96‏‎ (1 revision)
  430. ICRP Publication 44‏‎ (1 revision)
  431. Distribution coefficient‏‎ (1 revision)
  432. Secondary radiation‏‎ (1 revision)
  433. ICRP Publication 59‏‎ (1 revision)
  434. Intake‏‎ (1 revision)
  435. ICRP Publication 73‏‎ (1 revision)
  436. Standard-size adult‏‎ (1 revision)
  437. ICRP Publication 88‏‎ (1 revision)
  438. Epigenetic effects‏‎ (1 revision)
  439. 1928 Recommendations‏‎ (1 revision)
  440. Tissue reaction‏‎ (1 revision)
  441. Measured quantity‏‎ (1 revision)
  442. Tumour suppressor gene‏‎ (1 revision)
  443. National DRL‏‎ (1 revision)
  444. Additive risk projection model‏‎ (1 revision)
  445. Oxygen enhancement ratio‏‎ (1 revision)
  446. Population risk‏‎ (1 revision)
  447. ICRP Publication 106‏‎ (1 revision)
  448. ICRP Publication 12‏‎ (1 revision)
  449. ICRP Publication 134‏‎ (1 revision)
  450. Cobblestone area forming cell assay‏‎ (1 revision)
  451. ICRP Publication 149‏‎ (1 revision)
  452. ICRP Publication 23‏‎ (1 revision)
  453. DRL quantity‏‎ (1 revision)
  454. ICRP Publication 30 (Supplement to Part 2)‏‎ (1 revision)
  455. Detector quantum efficiency‏‎ (1 revision)
  456. ICRP Publication 97‏‎ (1 revision)
  457. ICRP Publication 45‏‎ (1 revision)
  458. Secretory cells‏‎ (1 revision)
  459. ICRP Publication 6‏‎ (1 revision)
  460. Intensity-modulated radiotherapy‏‎ (1 revision)
  461. ICRP Publication 74‏‎ (1 revision)
  462. Stem cell‏‎ (1 revision)
  463. Kerma approximation‏‎ (1 revision)
  464. ICRP Publication 89‏‎ (1 revision)
  465. Exogenous excretion‏‎ (1 revision)
  466. 1931 Recommendations‏‎ (1 revision)
  467. National radon survey‏‎ (1 revision)
  468. Adenoma‏‎ (1 revision)
  469. Potential alpha energy concentration‏‎ (1 revision)
  470. ICRP Publication 107‏‎ (1 revision)
  471. ICRP Publication 120‏‎ (1 revision)
  472. Carers and comforters‏‎ (1 revision)
  473. ICRP Publication 135‏‎ (1 revision)
  474. ICRP Publication 15‏‎ (1 revision)
  475. Redox‏‎ (1 revision)
  476. ICRP Publication 24‏‎ (1 revision)
  477. Relative biological effectiveness‏‎ (1 revision)
  478. ICRP Publication 31‏‎ (1 revision)
  479. Deterministic effect‏‎ (1 revision)
  480. ICRP Publication 98‏‎ (1 revision)
  481. ICRP Publication 46‏‎ (1 revision)
  482. ICRP Publication 60‏‎ (1 revision)
  483. Dose modifying factor‏‎ (1 revision)
  484. Somatic effect‏‎ (1 revision)
  485. ICRP Publication 75‏‎ (1 revision)
  486. ICRP Publication 9‏‎ (1 revision)
  487. Targeted effects‏‎ (1 revision)
  488. 1934 Recommendations‏‎ (1 revision)
  489. Access control‏‎ (1 revision)
  490. Typical value‏‎ (1 revision)
  491. General Information: Radon‏‎ (1 revision - redirect page)
  492. Particle transport‏‎ (1 revision)
  493. ICRP Publication 108‏‎ (1 revision)
  494. Brachytherapy‏‎ (1 revision)
  495. ICRP Publication 121‏‎ (1 revision)
  496. Case–control study‏‎ (1 revision)
  497. ICRP Publication 136‏‎ (1 revision)
  498. Collective dose‏‎ (1 revision)
  499. ICRP Publication 150‏‎ (1 revision)
  500. ICRP Publication 25‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"